Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence

Table 2

Cytoplasmic CD138 staining and prostate cancer phenotype.

Parameter	evaluable	Negative (%)	Weak (%)	Moderate (%)	Strong (%)	value
All cancers	12851	88.8	9.5	1.6	0.1
Tumor stage						<0.0001
pT2	8124	92.4	6.6	0.9	0.0
pT3a	2967	85.0	12.4	2.5	0.2
pT3b-pT4	1709	78.1	18.1	3.3	0.5
Gleason grade						<0.0001
≤3+3	2176	92.1	6.9	0.9	0.0
3+4	7016	90.9	7.9	1.1	0.0
3+4 Tert.5	632	87.7	10.6	1.7	0.0
4+3	1269	82.6	13.7	3.5	0.2
4+3 Tert.5	952	83.6	14.3	1.9	0.2
≥4+4	685	76.8	18.5	3.5	1.2
Quantitative Gleason grade
≤3+3	2176	92.1	6.9	0.9	0.0	<0.0001
	1683	93.5	5.6	0.8	0.1
3+4 6-10%	1786	92.1	7.2	0.6	0.1
3+4 11-20%	1577	91.6	7.4	1.0	0.0
3+4 21-30%	806	88.2	9.9	1.9	0.0
3+4 31-49%	614	87.9	9.3	2.8	0.0
3+4 Tert.5	632	87.7	10.6	1.7	0.0
4+3 50-60%	522	87.0	12.1	1.0	0.0
4+3 Tert.5	952	83.6	14.3	1.9	0.2
4+3 61-<100%	564	80.0	13.8	6.0	0.2
≥4+4	600	77.5	18.0	3.5	1.0
Lymph node metastasis						<0.0001
N0	7842	88.6	9.7	1.6	0.2
N+	935	79.0	18.2	2.5	0.3
Preoperative PSA level (ng/ml)						<0.0001
<4	1457	91.1	7.1	1.6	0.3
4-10	7580	90.3	8.3	1.3	0.1
10-20	2761	86.4	11.8	1.6	0.1
>20	976	80.7	15.6	3.4	0.3
Surgical margin						<0.0001
Negative	10114	89.7	8.9	1.3	0.1
Positive	2691	85.3	11.6	2.7	0.4